Bioxytran, Inc. announced that it has entered into 34 note purchase agreement with accredited investors for 1 year convertible notes for gross proceeds of $1,467,000 on January 5, 2022. The notes carry an interest rate of 6% and are convertible into shares of the company's common stock at a fixed price of $0.25. The transaction has been approved by the company's board of directors.

The notes contain an aggregate discount of $128,290. The minimum investment accepted from any outside investor is $2,500.